Marshall Wace, LLP Scynexis Inc Transaction History

Marshall Wace, LLP

  • $63.3 Billion
  • Q1 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 14, 2023
SELL
$1.93 - $3.64 $115,682 - $218,177
-59,939 Reduced 75.38%
19,580 $44,000
Q2 2023

Aug 14, 2023
BUY
$2.38 - $3.67 $189,255 - $291,834
79,519 New
79,519 $234,000
Q2 2021

Aug 13, 2021
BUY
$6.5 - $9.97 $560,878 - $860,301
86,289 New
86,289 $635,000

Others Institutions Holding SCYX

# of Institutions
57
Shares Held
15.4M
Call Options Held
0
Put Options Held
12.9K
View Full List

About SCYNEXIS INC

SCYX Quotes by TradingView
  • Ticker SCYX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 32,651,800
  • Market Cap $63.7M
  • Description
  • SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of vario...
More about SCYX
Track This Portfolio

Track Marshall Wace, LLP Portfolio

Follow Marshall Wace, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email